Active Biotech AB

Quick facts

Phase 2 pipeline

• ABR-215050, tasquinimod · Oncology
  Tasquinimod is a quinoline-3-carboxamide derivative that modulates the immune system by targeting the S100A9 protein.
• IFN-alpha · Oncology
  Interferes with viral replication by binding to the cell surface receptor for the virus.

Phase 1 pipeline

• ABR-215050
• ABR-217620

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Active Biotech AB portfolio CI brief
• Active Biotech AB pipeline updates RSS